To compare the constituent genes and benchmark performance of RBNSig-BC with previously identified signatures of RB loss, we collated a panel of eight RB-related signatures constituting five RB loss signatures of breast cancer (15, 18–20, 39), a proliferation signature (46), a pan-cancer RB1 loss signature (17), and a CDK2 activity signature (47). This evidence concerns the gene CDK2 and breast carcinoma.